A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
Crossref DOI link: https://doi.org/10.1007/s12072-016-9704-y
Published Online: 2016-02-04
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Takami, Yuko
Eguchi, Susumu
Tateishi, Masaki
Ryu, Tomoki
Mikagi, Kazuhiro
Wada, Yoshiyuki
Saitsu, Hideki
License valid from 2016-02-04